← Target Group Inc. (CBDY) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Target Group Inc. (CBDY)
Medicinal Chemicals & Botanical Products · market cap $431,918
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
9
programs
Upcoming events
0
next 90d+
Dossier
Not yet
generate it
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| OTL38 | Phase 3 | Ovarian Cancer |
| OTL38 for Injection | Phase 3 | Lung Neoplasms |
| Cytalux™ (pafolacianine) for fluorescent imaging | Phase 2 | Prostate Cancer |
| CYTALUX™ (pafolacianine) injection preoperatively | Phase 2 | Esophageal Cancer |
| NRX-101 Oral Capsule | Phase 2 | Bipolar Depression |
| NRX-101 | Phase 3 | Bipolar Depression |
| 0.03mg/kg ZOPOCIANINE given day of surgery | Phase 2 | Prostate Cancer Surgery |
| Ha44 Gel | Phase 2 | Head Lice Infestation |
| One POMx capsule daily | Phase 2 | Erectile Dysfunction |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CBDY (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 9 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.